



1 Gamma-linolenic acid versus placebo


1.1 Pain VAS 0-100 percentage change from baseline




1.2 Pain VAS 0-100 at 12 weeks




1.3 Pain (0 to 4) percentage change from baseline




1.4 Morning stiffness (minutes) percentage change from baseline




1.5 Morning stiffness (minutes) at 12 weeks




1.6 68 tender joint count percentage change from baseline




1.7 66 swollen joint count percentage change from baseline




1.8 Joint tenderness (0 to 3) percentage change from baseline




1.9 Joint swelling (0 to 3) percentage change from baseline




1.10 HAQ disability score percentage change from baseline




1.11 Patient global (0 to 4) percentage change from baseline




1.12 Physician global (0 to 4) percentage change from baseline




1.13 Participants (n) reported reduced NSAID use



1.14 Participants (n) reported adverse events




1.15 Participants (n) withdrawn due to worsening disease




2 Tripterygium wilfordii Hook F 60mg versus placebo


2.1 Joint tenderness (0 to 3)




2.2 60 swollen joint count




2.3 Morning stiffness (hours)



2.4 Grip strength (mmHg)




2.5 15 metre walking time (seconds)




3 Tripterygium wilfordii Hoof F 180mg versus placebo

3.1 ACR20 responders




3.2 Participants (n) reported adverse events




4 Tripterygium wilfordii Hook F 360mg versus placebo

4.1 ACR20 responders




4.2 Participants (n) reported adverse events




5 Phytodolor N versus placebo


5.1 Pain (0 to 3)




5.2 Cumulative NSAID use (diclofenac)




5.3 Joint swelling (0 to 3)



5.4 Morning stiffness (minutes)




5.5 Ritchie index




6 SKI306X versus celecoxib


6.1 Pain VAS 0-100 change from baseline




6.2 28 tender joint count




6.3 28 swollen joint count




6.4 Patient global VAS 0-100




6.5 Physician global VAS 0-100




6.6 Disability HAQ-DI score (0-3)



6.7 ACR20 responders




6.8 Participants (n) reported adverse events




7 Salix purpurea x daphnoides (willow bark) versus placebo


7.1 Pain VAS 0-100 change from baseline




7.2 28 tender joint count change from baseline




7.3 28 swollen joint count change from baseline




7.4 Patient assessment of efficacy VAS 0-100 change from baseline




7.5 Physician assessment of efficacy VAS 0-100 change from baseline




7.6 ACR20 responders




7.7 HAQ disability index change from baseline



7.8 SF-36 physical component summary score change from baseline




7.9 SF-36 mental component summary score change from baseline




8 Cat's claw versus placebo


8.1 Pain VAS 0-100




8.2 68 tender joint count




8.3 66 swollen joint count




8.4 Morning stiffness (0 to 5)



8.5 Ritchie index




8.6 Disease activity VAS 0-100




9 Feverfew versus placebo

9.1 Grip strength (mmHg) at 6 weeks




9.2 Participants (n) reported adverse events




10 RA-1 versus placebo


10.1 Pain VAS 0-100 change from baseline




10.2 68 tender joint count change from baseline




10.3 66 swollen joint count change from baseline




10.4 Modified HAQ (Pune) change from baseline




10.5 Patient global (1 to 5) change from baseline




10.6 Physician global (1 to 5) change from baseline



10.7 ACR20 responders




10.8 ACR50 responders




11 Capsaicin versus placebo


11.1 Pain VAS 0-100 percentage change at 4 weeks



11.2 Pain (0 to 4) change from baseline at 4 weeks




11.3 Physician global (-1 to 3) change from baseline at 4 weeks




12 Tripterygium wilfordii (topical) versus placebo


12.1 42 tender joint count at 6 weeks




12.2 40 swollen joint count at 6 weeks




12.3 Grip strength (kPa) at 6 weeks



12.4 Morning stiffness (hours) at 6 weeks




12.5 ACR20 responders at 6 weeks



13 Boswellia serrata versus placebo

13.1 Ritchie index pain percentage improvement at 12 weeks



13.2 Participants (n) reported adverse events

